New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...
March 24--Shares of DexCom gained more than 8 percent Friday after Medicare issued a favorable ruling for reimbursing use of continuous glucose monitors, made by the San Diego-based company. DexCom ...
DexCom presented outlook on diabetes market at the ADA Conference, highlighting potential for growth with new products like Stelo and DexCom ONE. DexCom's strategy differs from Abbott Labs, focusing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results